Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The role of glucagon-like peptide 1 (GLP-1) in addictive disorders

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. Exercise training as prophylactic strategy in the management of neutropenia during chemotherapy

    Research output: Contribution to journalReviewResearchpeer-review

  2. Advances in migraine and headache therapy (BJP 75th anniversary)

    Research output: Contribution to journalEditorialResearchpeer-review

  3. Metabolic control and sex: A focus on inflammatory-linked mediators

    Research output: Contribution to journalReviewResearchpeer-review

  4. Different mechanisms involved in liraglutide and glucagon-like peptide-1 vasodilatation in rat mesenteric small arteries

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Use of chlorprothixene and the risk of diabetes and major adverse cardiovascular events: A nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. SARS-CoV-2 seroprevalence among patients with severe mental illness: A cross-sectional study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Clozapine- and non-clozapine-associated neutropenia in patients with schizophrenia: a retrospective cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Possible Tacrolimus-Related Neuropsychiatric Symptoms: One Year After Allogeneic Hematopoietic Cell Transplantation: A Case Report

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Drug, alcohol and tobacco use disorders are a global burden affecting millions of people. Despite decades of research, treatment options are sparse or missing, and relapse rates are high. Glucagon-like peptide 1 (GLP-1) is released in the small intestine, promotes blood glucose homeostasis, slows gastric emptying and reduces appetite. GLP-1 receptor agonists approved for treating Type 2 diabetes mellitus and obesity have received attention as a potential anti-addiction treatment. Studies in rodents and non-human primates have demonstrated a reduction in intake of alcohol and drugs of abuse, and clinical trials have been initiated to investigate whether the preclinical findings can be translated to patients. This review will give an overview of current findings and discuss the possible mechanisms of action. We suggest that effects of GLP-1 in alcohol and substance use disorders is mediated centrally, at least partly through dopamine signalling, but precise mechanisms are still to be uncovered. LINKED ARTICLES: This article is part of a themed issue on GLP1 receptor ligands (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.4/issuetoc.

Original languageEnglish
JournalBritish Journal of Pharmacology
Volume179
Issue number4
Pages (from-to)625-641
Number of pages17
ISSN0007-1188
DOIs
Publication statusPublished - Feb 2022

Bibliographical note

This article is protected by copyright. All rights reserved.

ID: 69834664